成人失眠障碍急性期与长期药物治疗的比较效果:系统综述与网状Meta分析
该研究通过系统综述与网状Meta分析比较多种药物对成人失眠障碍的急性和长期疗效。纳入170项试验(36种干预、47950名参与者),网状Meta分析纳入154项双盲随机对照试验(30种干预、44089名参与者)。急性期苯二氮䓬类、多西拉敏、艾司佐匹克隆、莱博雷生、塞托雷生、唑吡坦和佐匹克隆比安慰剂更有效;长期艾司佐匹克隆和莱博雷生比安慰剂更有效。
要点
- 急性期苯二氮䓬类、多西拉敏、艾司佐匹克隆、莱博雷生、塞托雷生、唑吡坦和佐匹克隆比安慰剂有效(SMD 0.36-0.83)。
- 佐匹克隆和唑吡坦因不良事件导致的脱落多于安慰剂(佐匹克隆OR 2.00,唑吡坦OR 1.79)。
- 长期艾司佐匹克隆和莱博雷生比安慰剂有效,但证据确定性极低。
核心结论
- 总体而言,艾司佐匹克隆和莱博雷生具有有利的特征,但艾司佐匹克隆可能引起大量不良事件,莱博雷生的安全性数据尚无定论。
- 多塞平、塞托雷生和扎来普隆耐受性良好,但疗效和其他重要结局的数据稀少,无法得出明确结论。
- 许多许可药物(包括苯二氮䓬类、达利雷生、苏沃雷生和曲唑酮)在失眠急性期治疗中可能有效,但与耐受性差相关,或缺乏长期效果信息。
- 褪黑素、雷美替胺和未许可药物未显示出总体实质性获益。
研究设计与样本
- 系统综述与网状Meta分析,检索Cochrane对照试验中心注册库、MEDLINE、PubMed、Embase、PsycINFO、WHO国际临床试验注册平台、ClinicalTrials.gov及监管机构网站,从数据库建库至2021年11月25日。
- 纳入比较药物单药治疗或安慰剂治疗成人(≥18岁)失眠障碍的随机对照试验;系统综述纳入170项试验(36种干预、47950名参与者),网状Meta分析纳入154项双盲随机对照试验(30种干预、44089名参与者)。
- 使用CINeMA框架评估证据确定性,采用随机效应模型估计汇总标准化均数差(SMD)和比值比(OR)。
主要发现
- 急性期治疗中,苯二氮䓬类、多西拉敏、艾司佐匹克隆、莱博雷生、塞托雷生、唑吡坦和佐匹克隆比安慰剂更有效(SMD范围0.36-0.83,证据确定性高至中等);苯二氮䓬类、艾司佐匹克隆、唑吡坦和佐匹克隆比褪黑素、雷美替胺和扎来普隆更有效(SMD 0.27-0.71,证据确定性中至极低)。
- 急性期治疗中,中效苯二氮䓬类、长效苯二氮䓬类和艾司佐匹克隆因任何原因导致的停药少于雷美替胺(OR分别为0.72 [95%CI 0.52-0.99;中等]、0.70 [0.51-0.95;中等]和0.71 [0.52-0.98;中等])。
- 佐匹克隆和唑吡坦因不良事件导致的脱落多于安慰剂(佐匹克隆OR 2.00 [95%CI 1.28-3.13;极低],唑吡坦OR 1.79 [1.25-2.50;中等]);佐匹克隆因不良事件导致的脱落多于艾司佐匹克隆(OR 1.82 [1.01-3.33;低]、达利雷生(OR 3.45 [1.41-8.33;低])和苏沃雷生(OR 3.13 [1.47-6.67;低])。
- 研究终点时至少发生一次不良事件的患者数,苯二氮䓬类、艾司佐匹克隆、唑吡坦和佐匹克隆劣于安慰剂、多塞平、塞托雷生和扎来普隆(OR范围1.27-2.78,证据确定性高至极低)。
- 长期治疗中,艾司佐匹克隆和莱博雷生比安慰剂更有效(艾司佐匹克隆SMD 0.63 [95%CI 0.36-0.90;极低],莱博雷生SMD 0.41 [0.04-0.78;极低]);艾司佐匹克隆比雷美替胺(SMD 0.63 [0.16-1.10;极低])和唑吡坦(SMD 0.60 [0.00-1.20;极低])更有效。与雷美替胺相比,艾司佐匹克隆和唑吡坦的全因停药率更低(艾司佐匹克隆OR 0.43 [95%CI 0.20-0.93;极低],唑吡坦OR 0.43 [0.19-0.95;极低]);然而,唑吡坦因副作用导致的脱落多于安慰剂(OR 2.00 [95%CI 1.11-3.70;极低])。
临床怎么用
- 原文结论指出这些结果应服务于循证临床实践。
- 作者认为艾司佐匹克隆和莱博雷生总体特征有利,但艾司佐匹克隆可能引起大量不良事件,莱博雷生安全性数据尚无定论。
- 作者指出多塞平、塞托雷生和扎来普隆耐受性良好,但疗效和其他重要结局数据稀少,无法得出明确结论。
局限性
- 莱博雷生的安全性数据尚无定论。
- 多塞平、塞托雷生和扎来普隆的疗效和其他重要结局数据稀少,无法得出明确结论。
- 许多许可药物(包括苯二氮䓬类、达利雷生、苏沃雷生和曲唑酮)与耐受性差相关,或缺乏长期效果信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Behavioural, cognitive, and pharmacological interventions can all be effective for insomnia. However, because of inadequate resources, medications are more frequently used worldwide. We aimed to estimate the comparative effectiveness of pharmacological treatments for the acute and long-term treatment of adults with insomnia disorder. METHODS: In this systematic review and network meta-analysis, we searched the Cochrane Central Register of Controlled Trials, MEDLINE, PubMed, Embase, PsycINFO, WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and websites of regulatory agencies from database inception to Nov 25, 2021, to identify published and unpublished randomised controlled trials. We included studies comparing pharmacological treatments or placebo as monotherapy for the treatment of adults (≥18 year) with insomnia disorder. We assessed the certainty of evidence using the confidence in network meta-analysis (CINeMA) framework. Primary outcomes were efficacy (ie, quality of sleep measured by any self-rated scale), treatment discontinuation for any reason and due to side-effects specifically, and safety (ie, number of patients with at least one adverse event) both for acute and long-term treatment. We estimated summary standardised mean differences (SMDs) and odds ratios (ORs) using pairwise and network meta-analysis with random effects. This study is registered with Open Science Framework, https://doi.org/10.17605/OSF.IO/PU4QJ. FINDINGS: We included 170 trials (36 interventions and 47 950 participants) in the systematic review and 154 double-blind, randomised controlled trials (30 interventions and 44 089 participants) were eligible for the network meta-analysis. In terms of acute treatment, benzodiazepines, doxylamine, eszopiclone, lemborexant, seltorexant, zolpidem, and zopiclone were more efficacious than placebo (SMD range: 0·36-0·83 [CINeMA estimates of certainty: high to moderate]). Benzodiazepines, eszopiclone, zolpidem, and zopiclone were more efficacious than melatonin, ramelteon, and zaleplon (SMD 0·27-0·71 [moderate to very low]). Intermediate-acting benzodiazepines, long-acting benzodiazepines, and eszopiclone had fewer discontinuations due to any cause than ramelteon (OR 0·72 [95% CI 0·52-0·99; moderate], 0·70 [0·51-0·95; moderate] and 0·71 [0·52-0·98; moderate], respectively). Zopiclone and zolpidem caused more dropouts due to adverse events than did placebo (zopiclone: OR 2·00 [95% CI 1·28-3·13; very low]; zolpidem: 1·79 [1·25-2·50; moderate]); and zopiclone caused more dropouts than did eszopiclone (OR 1·82 [95% CI 1·01-3·33; low]), daridorexant (3·45 [1·41-8·33; low), and suvorexant (3·13 [1·47-6·67; low]). For the number of individuals with side-effects at study endpoint, benzodiazepines, eszopiclone, zolpidem, and zopiclone were worse than placebo, doxepin, seltorexant, and zaleplon (OR range 1·27-2·78 [high to very low]). For long-term treatment, eszopiclone and lemborexant were more effective than placebo (eszopiclone: SMD 0·63 [95% CI 0·36-0·90; very low]; lemborexant: 0·41 [0·04-0·78; very low]) and eszopiclone was more effective than ramelteon (0.63 [0·16-1·10; very low]) and zolpidem (0·60 [0·00-1·20; very low]). Compared with ramelteon, eszopiclone and zolpidem had a lower rate of all-cause discontinuations (eszopiclone: OR 0·43 [95% CI 0·20-0·93; very low]; zolpidem: 0·43 [0·19-0·95; very low]); however, zolpidem was associated with a higher number of dropouts due to side-effects than placebo (OR 2·00 [95% CI 1·11-3·70; very low]). INTERPRETATION: Overall, eszopiclone and lemborexant had a favorable profile, but eszopiclone might cause substantial adverse events and safety data on lemborexant were inconclusive. Doxepin, seltorexant, and zaleplon were well tolerated, but data on efficacy and other important outcomes were scarce and do not allow firm conclusions. Many licensed drugs (including benzodiazepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or information about long-term effects is not available. Melatonin, ramelteon, and non-licensed drugs did not show overall material benefits. These results should serve evidence-based clinical practice. FUNDING: UK National Institute for Health Research Oxford Health Biomedical Research Centre.
引用
- De Crescenzo F, D'Alò GL, Ostinelli EG, et al. Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet. 2022. PMID: 35843245. doi:10.1016/S0140-6736(22)00878-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。